Literature DB >> 25910454

Lymph Node Harvest During Esophagectomy Is Not Influenced by Use of Neoadjuvant Therapy or Clinical Disease Stage.

Renato A Luna1, James P Dolan, Brian S Diggs, Nathan W Bronson, Brett C Sheppard, Paul H Schipper, Brandon H Tieu, Benjamin T Feeney, Ken M Gatter, Gina M Vaccaro, Charles R Thomas, John G Hunter.   

Abstract

INTRODUCTION: The purpose of this study was to evaluate the effects of neoadjuvant therapy on lymph node harvest (LNH), lymph node ratio (LNR), and overall survival rates after esophagectomy.
METHODS: A retrospective analysis of 111 patients who underwent esophagectomy for esophageal adenocarcinoma from 2001 to 2010 was performed. Patients were divided into two groups: neoadjuvant chemoradiotherapy prior to surgery (NEOSURG) versus surgery alone (SURG).
RESULTS: There were 83 patients (75%) in the NEOSURG group and 28 (25%) in the SURG group with a mean age of 66 and 67 years, respectively. The median LNH in the NEOSURG group and SURG group was 16.0 and 15.5, respectively (p = 0.57). Within the NEOSURG group, the median LNH was 16 for complete responders, 14 for partial responders, 16 for nonresponders, and 18 in those who were pathologically upstaged (p = 0.434). The median LNR was 0, 0, 0.1, and 0.2, respectively (p < 0.001). Complete response after neoadjuvant therapy demonstrated a trend toward improved survival (p = 0.056).
CONCLUSION: The LNH was not significantly influenced by neoadjuvant treatment or pathologic response. The LNR was inversely related to pathologic response after neoadjuvant therapy. Complete pathologic response to neoadjuvant therapy trends to improve survival rates.

Entities:  

Mesh:

Year:  2015        PMID: 25910454     DOI: 10.1007/s11605-015-2821-4

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  24 in total

1.  Long-term outcomes following neoadjuvant chemoradiotherapy in patients with clinical T2N0 esophageal squamous cell carcinoma.

Authors:  W-H Chen; Y-K Chao; H-K Chang; C-K Tseng; Y-C Wu; Y-H Liu; M-J Hsieh; H-P Liu
Journal:  Dis Esophagus       Date:  2011-09-23       Impact factor: 3.429

2.  T2N0M0 esophageal cancer.

Authors:  Thomas W Rice; David P Mason; Sudish C Murthy; Gregory Zuccaro; David J Adelstein; Lisa A Rybicki; Eugene H Blackstone
Journal:  J Thorac Cardiovasc Surg       Date:  2007-01-09       Impact factor: 5.209

3.  The assessment of prognosis of surgically resected oesophageal cancer is dependent on the number of lymph nodes examined pathologically.

Authors:  Christopher P Twine; Wyn G Lewis; Matthew A Morgan; David Chan; Geoffrey W B Clark; Tim Havard; Tom D Crosby; S Ashley Roberts; Geriant T Williams
Journal:  Histopathology       Date:  2009-07       Impact factor: 5.087

4.  Clinical T2-T3N0M0 esophageal cancer: the risk of node positive disease.

Authors:  Brendon M Stiles; Farooq Mirza; Anthony Coppolino; Jeffrey L Port; Paul C Lee; Subroto Paul; Nasser K Altorki
Journal:  Ann Thorac Surg       Date:  2011-06-24       Impact factor: 4.330

5.  Eliminating the cervical esophagogastric anastomotic leak with a side-to-side stapled anastomosis.

Authors:  M B Orringer; B Marshall; M D Iannettoni
Journal:  J Thorac Cardiovasc Surg       Date:  2000-02       Impact factor: 5.209

6.  Complete response to preoperative chemoradiation and survival in esophageal cancer: a pooled analysis of three single-institution phase II trials.

Authors:  M Orditura; G Galizia; F Morgillo; E Martinelli; E Lieto; F Vitiello; N Di Martino; R Pacelli; A Renda; F Ciardiello; F De Vita
Journal:  Dis Esophagus       Date:  2011-07-15       Impact factor: 3.429

7.  Predictors of survival in patients with persistent nodal metastases after preoperative chemotherapy for esophageal cancer.

Authors:  Brendon M Stiles; Paul Christos; Jeffrey L Port; Paul C Lee; Subroto Paul; James Saunders; Nasser K Altorki
Journal:  J Thorac Cardiovasc Surg       Date:  2009-12-16       Impact factor: 5.209

8.  Total number of resected lymph nodes predicts survival in esophageal cancer.

Authors:  Nasser K Altorki; Xi Kathy Zhou; Brendon Stiles; Jeffrey L Port; Subroto Paul; Paul C Lee; Madhu Mazumdar
Journal:  Ann Surg       Date:  2008-08       Impact factor: 12.969

9.  A randomized study of chemotherapy, radiation therapy, and surgery versus surgery for localized squamous cell carcinoma of the esophagus.

Authors:  E Le Prise; P L Etienne; B Meunier; G Maddern; M Ben Hassel; D Gedouin; D Boutin; J P Campion; B Launois
Journal:  Cancer       Date:  1994-04-01       Impact factor: 6.860

10.  Neoadjuvant chemotherapy and surgery for esophageal adenocarcinoma: prognostic value of circumferential resection margin and stratification of N1 category.

Authors:  Arin Kumar Saha; Christopher Sutton; Olorunda Rotimi; Simon Dexter; Henry Sue-Ling; Abeezar I Sarela
Journal:  Ann Surg Oncol       Date:  2009-02-28       Impact factor: 5.344

View more
  3 in total

Review 1.  Pathologic assessment of gastrointestinal tract and pancreatic carcinoma after neoadjuvant therapy.

Authors:  Reetesh K Pai; Rish K Pai
Journal:  Mod Pathol       Date:  2017-08-04       Impact factor: 7.842

2.  Neoadjuvant therapy in relation to lymphadenectomy and resection margins during surgery for oesophageal cancer.

Authors:  Joonas H Kauppila; Karl Wahlin; Pernilla Lagergren; Jesper Lagergren
Journal:  Sci Rep       Date:  2018-01-11       Impact factor: 4.379

3.  Impact of the number of resected lymph nodes on survival after preoperative radiotherapy for esophageal cancer.

Authors:  San-Gang Wu; Zhao-Qiang Zhang; Wen-Ming Liu; Zhen-Yu He; Feng-Yan Li; Huan-Xin Lin; Jia-Yuan Sun; Hui Lin; Qun Li
Journal:  Oncotarget       Date:  2016-04-19
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.